Trial Profile

DISCERN: Dual Immune Strategy Versus Single Checkpoint Inhibition Efficacy Response in PDL-1 Negative Non-Small Cell Lung Cancer (NSCLC)

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 29 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary)
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Pharmacodynamics; Therapeutic Use
Acronyms DISCERN

Most Recent Events

27 Jan 2025 Planned End Date changed from 1 Jul 2027 to 1 Sep 2027.
27 Jan 2025 Planned primary completion date changed from 27 Feb 2027 to 27 Apr 2027.
27 Jan 2025 Planned initiation date changed from 31 Jan 2025 to 31 Mar 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com